ueda2013 primary prevention-d.lobna
-
Upload
ueda2015 -
Category
Health & Medicine
-
view
39 -
download
0
Transcript of ueda2013 primary prevention-d.lobna
![Page 1: ueda2013 primary prevention-d.lobna](https://reader033.fdocuments.net/reader033/viewer/2022052700/55c8c4cbbb61ebda1c8b46e5/html5/thumbnails/1.jpg)
Primary prevention : From Theory to real clinical evidence (insights from Jupiter trial)
Lobna Farag Eltoony Head of diabetes and Endocrinology Unit
Department Of Internal Medicine Asst University
![Page 2: ueda2013 primary prevention-d.lobna](https://reader033.fdocuments.net/reader033/viewer/2022052700/55c8c4cbbb61ebda1c8b46e5/html5/thumbnails/2.jpg)
Dyslipidemia (35.6%)
Diabetes Mellitus (8.7%) None (53.2%)
Hypertension (27.6%)
NHANES III = The Third National Health and Nutrition Examination Survey.
* Estimates based on application of age- and sex-specific prevalence estimates for each condition from the NHANES III data to the Kaiser Permanente
membership to simulate full ascertainment.
Selby JV et al. Am J Manag Care. 2004;10:163–170.
Overlap of Diabetes
and Hypertension
~70% of Diabetes
~22% of Hypertension
Prevalence of Vascular Disease Risk Factors Among Adults Aged >20 Years*
![Page 3: ueda2013 primary prevention-d.lobna](https://reader033.fdocuments.net/reader033/viewer/2022052700/55c8c4cbbb61ebda1c8b46e5/html5/thumbnails/3.jpg)
Inflammation drives many stages of the atherosclerotic process and
the major mechanisms are illustrated here.
Oh J et al. Dia Care 2011;34:S155-S160
Copyright © 2011 American Diabetes Association, Inc.
![Page 4: ueda2013 primary prevention-d.lobna](https://reader033.fdocuments.net/reader033/viewer/2022052700/55c8c4cbbb61ebda1c8b46e5/html5/thumbnails/4.jpg)
Atherosclerosis: An Inflammatory Disease
III.2
© 2002 PPS®
C
![Page 5: ueda2013 primary prevention-d.lobna](https://reader033.fdocuments.net/reader033/viewer/2022052700/55c8c4cbbb61ebda1c8b46e5/html5/thumbnails/5.jpg)
The Function of HDL
![Page 6: ueda2013 primary prevention-d.lobna](https://reader033.fdocuments.net/reader033/viewer/2022052700/55c8c4cbbb61ebda1c8b46e5/html5/thumbnails/6.jpg)
Diabetes Vasc Dis Res 2007;4(suppl 3):S5–S8
Antiatherogenic actions of HDL
![Page 7: ueda2013 primary prevention-d.lobna](https://reader033.fdocuments.net/reader033/viewer/2022052700/55c8c4cbbb61ebda1c8b46e5/html5/thumbnails/7.jpg)
Note: Risk estimates were derived from the experience of the Framingham Heart Study,
a predominantly Caucasian population in Massachusetts, USA.
Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in
Adults.
JAMA. 2001;285:2486-2497.
Assessing CHD Risk in Men Step 1: Age
Years Points
20-34 -9
35-39 -4
40-44 0
45-49 3
50-54 6
55-59 8
60-64 10
65-69 11
70-74 12
75-79 13
Step 2: Total Cholesterol
TC Points at Points at Points at Points
at Points at
(mg/dL) Age 20-39 Age 40-49 Age 50-59 Age 60-69 Age
70-79
<160 0 0 0 0 0
160-199 4 3 2 1 0
200-239 7 5 3 1 0
240-279 9 6 4 2 1
280 11 8 5 3 1
HDL-C
(mg/dL) Points
60 -1
50-59 0
40-49 1
<40 2
Step 3: HDL-Cholesterol
Systolic BP Points Points
(mm Hg) if Untreated if Treated
<120 0 0
120-129 0 1
130-139 1 2
140-159 1 2
160 2 3
Step 4: Systolic Blood Pressure
Step 5: Smoking Status
Points at Points at Points at Points
at Points at
Age 20-39 Age 40-49 Age 50-59 Age 60-69 Age
70-79
Nonsmoker 0 0 0 0 0
Smoker 8 5 3 1 1
Age
Total cholesterol
HDL-cholesterol
Systolic blood pressure
Smoking status
Point total
Step 6: Adding Up the Points
Point Total 10-Year Risk Point Total 10-Year
Risk
<0 <1% 11 8%
0 1% 12 10%
1 1% 13 12%
2 1% 14 16%
3 1% 15 20%
4 1% 16 25%
5 2% 17 30%
6 2%
7 3%
8 4%
9 5%
10 6%
Step 7: CHD Risk
ATP III Framingham Risk Scoring
http://www.nhlbi.nih.gov/guidelines/cholesterol/index.htm
© 2001, Professional Postgraduate Services® www.lipidhealth.org
![Page 8: ueda2013 primary prevention-d.lobna](https://reader033.fdocuments.net/reader033/viewer/2022052700/55c8c4cbbb61ebda1c8b46e5/html5/thumbnails/8.jpg)
Risk Categorization
• Typical 10 year risk of stroke or myocardial infarction
• Low risk = < 15 percent
• Medium risk = 15-20 percent
• High risk = 20-30 percent
• Very high risk > 30 percent
![Page 9: ueda2013 primary prevention-d.lobna](https://reader033.fdocuments.net/reader033/viewer/2022052700/55c8c4cbbb61ebda1c8b46e5/html5/thumbnails/9.jpg)
LDL-C Treatment Goals
• Markedly elevated single risk factors such as familial
dyslipidaemias and severe hypertension.
• Calculated SCORE ≥5% and <10%.
115
mg/dl
100
mg/dl
70
mg/dl
Moderate
Risk
High
Risk
Very
High
Risk
• Documented CVD (CAD, stroke & PVD)
• Type 2 or type 1 diabetes with target organ damage
(such as microalbuminuria).
• Moderate to severe CKD (GFR <60 mL/min/1.73 m2).
• Calculated SCORE ≥10%.
Calculated SCORE ≥1% and <5%.
ESC/EAS
2011
Guidelines
ESC/EAS GUIDELINES. Zˇ eljko Reiner et al. European Heart Journal (2011) 32, 1769–1818
![Page 10: ueda2013 primary prevention-d.lobna](https://reader033.fdocuments.net/reader033/viewer/2022052700/55c8c4cbbb61ebda1c8b46e5/html5/thumbnails/10.jpg)
Relationship Between Changes in LDL-C and HDL-C Levels and CHD Risk
Pederson TR et al. Circulation 1998;97:1453-1460
![Page 11: ueda2013 primary prevention-d.lobna](https://reader033.fdocuments.net/reader033/viewer/2022052700/55c8c4cbbb61ebda1c8b46e5/html5/thumbnails/11.jpg)
Fitchett DH, Leiter LA, et al. Can J Cardiol 2005;21:85-90
LDL-C Lowering and the associated reduction of CV outcomes
![Page 12: ueda2013 primary prevention-d.lobna](https://reader033.fdocuments.net/reader033/viewer/2022052700/55c8c4cbbb61ebda1c8b46e5/html5/thumbnails/12.jpg)
Sachdeva et al, Am Heart J 2009;157:111-7.e2.
LDLC Levels in 136,905 Patients Hospitalized With CAD: 2000- 2006
LDLC (mg/dL) 130-160 > 160 < 130
Majority of patients hospitalised with CAD had Normal LDL-C
![Page 13: ueda2013 primary prevention-d.lobna](https://reader033.fdocuments.net/reader033/viewer/2022052700/55c8c4cbbb61ebda1c8b46e5/html5/thumbnails/13.jpg)
Prevalence of conventional risk factors† in male patients with CHD
None
One
Two
Three
Four (0.9%)
Total male patients=87 869 CHD=coronary heart disease
†smoking, hypertension, hypercholesterolaemia and diabetes mellitus
19.4%
43.0%
27.8%
8.9%
Adapted from Khot et al. JAMA 2003;290:898-904.
More than 90% of CHD Male patients had ≤2 risk factors
![Page 14: ueda2013 primary prevention-d.lobna](https://reader033.fdocuments.net/reader033/viewer/2022052700/55c8c4cbbb61ebda1c8b46e5/html5/thumbnails/14.jpg)
Mohamed A. Wahab EL AHLY Club player
Died in a match
No One is immune
![Page 15: ueda2013 primary prevention-d.lobna](https://reader033.fdocuments.net/reader033/viewer/2022052700/55c8c4cbbb61ebda1c8b46e5/html5/thumbnails/15.jpg)
Is it just Another Angle ?
Or
Are we looking in the wrong direction ?
![Page 16: ueda2013 primary prevention-d.lobna](https://reader033.fdocuments.net/reader033/viewer/2022052700/55c8c4cbbb61ebda1c8b46e5/html5/thumbnails/16.jpg)
Circulation 108: 250-252
A Multimarker Approach Should Focus
on Multiple Mechanisms / Pathologies
![Page 17: ueda2013 primary prevention-d.lobna](https://reader033.fdocuments.net/reader033/viewer/2022052700/55c8c4cbbb61ebda1c8b46e5/html5/thumbnails/17.jpg)
Hs-CRP
![Page 18: ueda2013 primary prevention-d.lobna](https://reader033.fdocuments.net/reader033/viewer/2022052700/55c8c4cbbb61ebda1c8b46e5/html5/thumbnails/18.jpg)
Inflammatory Markers: From Concept to Clinical Practice to Clinical Benefits:
Why the JUPITER Trial? , Presented by Paul M. Ridker, MD, MPH
![Page 19: ueda2013 primary prevention-d.lobna](https://reader033.fdocuments.net/reader033/viewer/2022052700/55c8c4cbbb61ebda1c8b46e5/html5/thumbnails/19.jpg)
Have trials really tested this direction?
![Page 20: ueda2013 primary prevention-d.lobna](https://reader033.fdocuments.net/reader033/viewer/2022052700/55c8c4cbbb61ebda1c8b46e5/html5/thumbnails/20.jpg)
4S
CARE
WOSCOPS
AFCAPS/TexCAPS
LIPID
No history of CHD or MI,low LDL-C,
HsCRP2mg/dl
JUPITER
The Pyramid of Recent Trials Relative Size of the Various Segments of the Population
Very high cholesterol with CHD or MI
Moderately high cholesterol in high risk CHD or MI
Normal cholesterol with CHD or MI
High cholesterol without CHD or MI
No history of CHD or MI Stat
in t
he
rap
y fr
om
On
e s
ucc
ess
to
an
oth
er
![Page 21: ueda2013 primary prevention-d.lobna](https://reader033.fdocuments.net/reader033/viewer/2022052700/55c8c4cbbb61ebda1c8b46e5/html5/thumbnails/21.jpg)
To investigate whether rosuvastatin 20 mg compared to
placebo would decrease the rate of first major cardiovascular
events among apparently healthy men and women with
LDL < 130 mg/dL (3.36 mmol/L) who are nonetheless
at increased vascular risk on the basis of an enhanced
inflammatory response, as determined by hsCRP > 2 mg/L.
To enroll large numbers of women and individuals of Black or
Hispanic ethnicity, groups for whom little data on primary
prevention with statin therapy exists.
Justification for the Use of statins in Prevention:
an Intervention Trial Evaluating Rosuvastatin
Ridker et al NEJM 2008
![Page 22: ueda2013 primary prevention-d.lobna](https://reader033.fdocuments.net/reader033/viewer/2022052700/55c8c4cbbb61ebda1c8b46e5/html5/thumbnails/22.jpg)
Is it LDL or inflammation or both?
![Page 23: ueda2013 primary prevention-d.lobna](https://reader033.fdocuments.net/reader033/viewer/2022052700/55c8c4cbbb61ebda1c8b46e5/html5/thumbnails/23.jpg)
PREVENTING THE FIRST MYOCARDIAL INFARCTION: PRIMARY
ENDPOINTS
At different LDL levels in these trials …. Placebo showed high no. of
events …. It seems it is not LDL alone
WOSCOPS AFCAPS MEGA JUPITER N = 6595 N = 6605 N = 7832 N = 17802
Fatal and nonfatal
MI
Fatal and nonfatal MI, unstable angina,
sudden cardiac death
Fatal and nonfatal
MI
15.4 10.9 5.0 14.8 Events per 1000 pt.yrs in placebo group
Prava 40 Lova 20 – 40 Prava 10 – 20 Rosuva 20
MI, stroke, unstable angina,
revascularisation, CV death.
![Page 24: ueda2013 primary prevention-d.lobna](https://reader033.fdocuments.net/reader033/viewer/2022052700/55c8c4cbbb61ebda1c8b46e5/html5/thumbnails/24.jpg)
1.00
0.99
0.98
0.97
0.96
0.00 0 2 4 6 8
Years of Follow-up
Primary Prevention : Whom Should We Treat ?
Ridker et al, N Engl J Med. 2002;347:1557-1565.
Pro
bab
ility
of
Eve
nt-
fre
e S
urv
ival
hsCRP < 2, LDL < 130
hsCRP > 2, LDL > 130
hsCRP < 2, LDL > 130
hsCRP > 2, LDL < 130
![Page 25: ueda2013 primary prevention-d.lobna](https://reader033.fdocuments.net/reader033/viewer/2022052700/55c8c4cbbb61ebda1c8b46e5/html5/thumbnails/25.jpg)
However, while intriguing and of potential public health importance, the
observation in AFCAPS/TexCAPS that statin therapy might be effective
among those with elevated hsCRP but low cholesterol was made on a
post hoc basis. Thus, a large-scale randomized trial of statin therapy was
needed to directly test this hypotheses. Ridker et al New Engl J Med 2001;344:1959-65
Ridker et al, New Engl J Med 2001;344:1959-65
Low LDL, Low hsCRP
Low LDL, High hsCRP
Statin Effective Statin Not Effective
1.0 2.0 0.5
[A]
[B]
Low LDL, Low hsCRP
Low LDL, High hsCRP
Statin Effective Statin Not Effective
1.0 2.0 0.5
AFCAPS/TexCAPS Low LDL Subgroups
RR
AFCAPS/TEXCAPS showed statins to be effective in
lowering risk in the setting of normal LDL-C, but only when
inflammation was present
![Page 26: ueda2013 primary prevention-d.lobna](https://reader033.fdocuments.net/reader033/viewer/2022052700/55c8c4cbbb61ebda1c8b46e5/html5/thumbnails/26.jpg)
Jupiter : A different approach
![Page 27: ueda2013 primary prevention-d.lobna](https://reader033.fdocuments.net/reader033/viewer/2022052700/55c8c4cbbb61ebda1c8b46e5/html5/thumbnails/27.jpg)
JUPITER Trial Study Group, Am J Cardiol 2007; 100: 1659-1664.
Comparison of the Population in Statin trials Previous to Jupiter Trial Primary Prevention
WOSCOPS AFCAPS
Sample size (n) Small No. 6,595 6,605
Women (n) Not
represented 0 997
Non-Caucasian (n)
Not
represented
0 350
Duration (yrs) 4.9 5.2
Diabetes (%) 1 6
Baseline LDL-C (mg/dL) High 192 150
Baseline HDL-C (mg/dL) 44 36-40
Baseline TG (mg/dL) 164 158
Baseline hsCRP (mg/L) Not Tested NA NA
Intervention Pravastatin
40 mg
Lovastatin
10-40 mg
![Page 28: ueda2013 primary prevention-d.lobna](https://reader033.fdocuments.net/reader033/viewer/2022052700/55c8c4cbbb61ebda1c8b46e5/html5/thumbnails/28.jpg)
JUPITER Trial Study Group, Am J Cardiol 2007; 100: 1659-1664.
Comparison of the JUPITER Trial Population to Previous Statin Trials of Primary Prevention
JUPITER WOSCOPS AFCAPS
Sample size (n) 17,802 6,595 6,605
Women (n) 6,801 0 997
Non-Caucasian (n) 5,118 0 350
Duration (yrs) 1.9 (max 5) 4.9 5.2
Diabetes (%) 0 1 6
Baseline LDL-C (mg/dL) 104 192 150
Baseline HDL-C (mg/dL) 49 44 36-40
Baseline TG (mg/dL) 118 164 158
Baseline hsCRP (mg/L) >2 NA NA
Intervention Rosuvastatin
20 mg Pravastatin
40 mg
Lovastatin
10-40 mg
![Page 29: ueda2013 primary prevention-d.lobna](https://reader033.fdocuments.net/reader033/viewer/2022052700/55c8c4cbbb61ebda1c8b46e5/html5/thumbnails/29.jpg)
4021
2873
2497
2020
987 804
741 487
345 336 327 273 270 253 222 209 204 202 197 162 143 85 83 32 15 14 0
5
10
15
20
25
Ran
do
miz
atio
ns
(% T
ota
l.)
Total Randomized = 17,802
JUPITER: 17,802 Patients, 1,315 Sites, 26 Countries
![Page 30: ueda2013 primary prevention-d.lobna](https://reader033.fdocuments.net/reader033/viewer/2022052700/55c8c4cbbb61ebda1c8b46e5/html5/thumbnails/30.jpg)
8,155 fully complete
8,864 Vital status known
22 % d/c study med
8.0 % withdrew
4.4 % non-trial statin
JUPITER: Inclusion/Exclusion Criteria, Study Flow
89,890 screened
Inclusion criteria Men >50 years Women >60 years No CVD, No DM LDL <130 mg/dL hsCRP >2 mg/dL
4 week Placebo Run-in
Reason for Exclusion % LDL>130 mg/dL 52 hsCRP<2 mg/L 36 Withdrew consent 5 Diabetes 1 Hypothyroid <1 Liver disease <1 TG >600 mg/dL <1 Age out of range <1 Current use of HRT <1 Cancer <1 Poor compliance/Other <1 17,802 Randomized
8901 assigned to Rosuvastatin 20 mg
8901 assigned to Placebo
8,901 Included in Efficacy
and Safety Analyses
8,901 Included in Efficacy
and Safety Analyses
8,169 fully complete
8,857 Vital status known
19 % d/c study med
7.8 % withdrew
2.0 % non-trial statin
![Page 31: ueda2013 primary prevention-d.lobna](https://reader033.fdocuments.net/reader033/viewer/2022052700/55c8c4cbbb61ebda1c8b46e5/html5/thumbnails/31.jpg)
JUPITER – study design- started 2006 and scheduled to close in June 2011
Ridker PM. Circulation 2003; 108: 2292–2297
Lipids CRP
Tolerability
Lipids CRP
Tolerability HbA1C
Placebo
run-in
1 –6
2 –4
3 0
4 13
Final 3–4 y 6-monthly
Visit: Week:
Randomisation
Lipids CRP
Tolerability
Rosuvastatin 20 mg (n~7500)
Placebo (n~7500)
Lead-in/ eligibility
No history of CAD
men ≥50 yrs
women ≥60 yrs
LDL-C <130 mg/dL
CRP ≥2.0 mg/L
CAD=coronary artery disease; LDL-C=low-density lipoprotein cholesterol; CRP=C-reactive protein; HbA1c=glycated haemoglobin
![Page 32: ueda2013 primary prevention-d.lobna](https://reader033.fdocuments.net/reader033/viewer/2022052700/55c8c4cbbb61ebda1c8b46e5/html5/thumbnails/32.jpg)
The Jupiter Patients
![Page 33: ueda2013 primary prevention-d.lobna](https://reader033.fdocuments.net/reader033/viewer/2022052700/55c8c4cbbb61ebda1c8b46e5/html5/thumbnails/33.jpg)
- Av. Age = 66 y - 16 % Smokers - Av S.B.P = 134-145 - 41 % Metabolic Syndrome - 11% F. history of CV problems
![Page 34: ueda2013 primary prevention-d.lobna](https://reader033.fdocuments.net/reader033/viewer/2022052700/55c8c4cbbb61ebda1c8b46e5/html5/thumbnails/34.jpg)
Nizzar Qabbani .... Died with MI in 1998
![Page 35: ueda2013 primary prevention-d.lobna](https://reader033.fdocuments.net/reader033/viewer/2022052700/55c8c4cbbb61ebda1c8b46e5/html5/thumbnails/35.jpg)
CRESTOR OUTCOMES STUDY JUPITER CLOSES EARLY DUE TO UNEQUIVOCAL
EVIDENCE OF BENEFIT
JUPITER- Trial Stopped March 31st, 2008
![Page 36: ueda2013 primary prevention-d.lobna](https://reader033.fdocuments.net/reader033/viewer/2022052700/55c8c4cbbb61ebda1c8b46e5/html5/thumbnails/36.jpg)
Why stopped early?
![Page 37: ueda2013 primary prevention-d.lobna](https://reader033.fdocuments.net/reader033/viewer/2022052700/55c8c4cbbb61ebda1c8b46e5/html5/thumbnails/37.jpg)
Why stopped early?
![Page 38: ueda2013 primary prevention-d.lobna](https://reader033.fdocuments.net/reader033/viewer/2022052700/55c8c4cbbb61ebda1c8b46e5/html5/thumbnails/38.jpg)
Ridker said : It's okay with me if these physicians want to ignore the data. I just don't want them taking care of my patients or my family."
For physicians who thought it was better not to stop :
![Page 39: ueda2013 primary prevention-d.lobna](https://reader033.fdocuments.net/reader033/viewer/2022052700/55c8c4cbbb61ebda1c8b46e5/html5/thumbnails/39.jpg)
Rosuvastatin
Placebo 8901 8353 3872 1333 534 173
8901 8412 3892 1352 543 156
Number at risk Years
0
1
2
4
6
7
8
9
0 1 2 3 4
HR 0.56 (95% CI 0.46-0.69) P=<0.00001
Rosuvastatin Placebo
3
5
44%
JUPITER:
Primary Endpoint (composite end point) C
um
ula
tive
inci
de
nce
, %
Number of events 142 (1.6%) 252 (2.8%)
![Page 40: ueda2013 primary prevention-d.lobna](https://reader033.fdocuments.net/reader033/viewer/2022052700/55c8c4cbbb61ebda1c8b46e5/html5/thumbnails/40.jpg)
Who will benefit ?
![Page 41: ueda2013 primary prevention-d.lobna](https://reader033.fdocuments.net/reader033/viewer/2022052700/55c8c4cbbb61ebda1c8b46e5/html5/thumbnails/41.jpg)
0.25 0.5 1.0 2.0 4.0
Rosuvastatin Superior Rosuvastatin Inferior
Men
Women
Age ≤ 65 Age > 65
Smoker Non-Smoker
Caucasian
Non-Caucasian
USA/Canada
Rest of World
Hypertension
No Hypertension
All Participants
N P for Interaction
11,001 0.80
6,801
8,541 0.32
9,261
2,820 0.63
14,975
12,683 0.57
5,117
6,041 0.51
11,761
10,208 0.53
7,586
17,802
JUPITER:
Primary Endpoint – Subgroup Analysis I
![Page 42: ueda2013 primary prevention-d.lobna](https://reader033.fdocuments.net/reader033/viewer/2022052700/55c8c4cbbb61ebda1c8b46e5/html5/thumbnails/42.jpg)
HR 0.63 (95% CI 0.41-0.98) P = 0.04
Black, Hispanic, Other (N = 5,019)
HR 0.55 (95% CI 0.43-0.69) P < 0.0001
Caucasian (N = 12,683)
0 1 2 3 4
0.0
0
0.0
2
0.0
4
0.0
6
0.0
8
0.1
0
Cu
mu
lati
ve In
cid
en
ce
Follow-up (years)
Placebo
Rosuvastatin
0 1 2 3 4
Follow-up (years)
Placebo
Rosuvastatin
JUPITER:
Primary Endpoint By Ethnicity
![Page 43: ueda2013 primary prevention-d.lobna](https://reader033.fdocuments.net/reader033/viewer/2022052700/55c8c4cbbb61ebda1c8b46e5/html5/thumbnails/43.jpg)
JUPITER
Primary Endpoint According to Baseline Glucose Levels
HR 0.51, 95% CI 0.40-0.67
P < 0.0001
Normal Fasting Glucose
HR 0.69, 95% CI 0.49-0.98
P= 0.04
Impaired Fasting Glucose
0 1 2 3 4
Follow-up Years
0.0
0
0.0
2
0.0
4
0.0
6
0.0
8
0.1
0
Cu
mu
lati
ve In
cid
ence
0 1 2 3 4
Follow-up Years
Rosuvastatin
Rosuvastatin
Placebo Placebo
![Page 44: ueda2013 primary prevention-d.lobna](https://reader033.fdocuments.net/reader033/viewer/2022052700/55c8c4cbbb61ebda1c8b46e5/html5/thumbnails/44.jpg)
Jupiter Benefits
![Page 45: ueda2013 primary prevention-d.lobna](https://reader033.fdocuments.net/reader033/viewer/2022052700/55c8c4cbbb61ebda1c8b46e5/html5/thumbnails/45.jpg)
- 54 %
0 1 2 3 4
Follow-up Years
0.5
1
1.5
2
2.5
3
Cu
mu
lati
ve In
cid
ence
JUPITER:
Fatal or Nonfatal Myocardial Infarction
HR 0.46 (95% CI 0.30-0.70) P<0.0002
Rosuvastatin Placebo
Number of events 31 68
![Page 46: ueda2013 primary prevention-d.lobna](https://reader033.fdocuments.net/reader033/viewer/2022052700/55c8c4cbbb61ebda1c8b46e5/html5/thumbnails/46.jpg)
Talaat El Sadaat Died 2012
MI Famous Politician
![Page 47: ueda2013 primary prevention-d.lobna](https://reader033.fdocuments.net/reader033/viewer/2022052700/55c8c4cbbb61ebda1c8b46e5/html5/thumbnails/47.jpg)
![Page 48: ueda2013 primary prevention-d.lobna](https://reader033.fdocuments.net/reader033/viewer/2022052700/55c8c4cbbb61ebda1c8b46e5/html5/thumbnails/48.jpg)
0 1 2 3 4
0.5
1
1.5
2
2.5
3
JUPITER:
Fatal or Nonfatal Stroke
Rosuvastatin Placebo
HR 0.52 (95% CI 0.34-0.79) P=0.002
- 48 %
Follow-up Years
Cu
mu
lati
ve In
cid
en
ce,
%
Number of events 33 64
![Page 49: ueda2013 primary prevention-d.lobna](https://reader033.fdocuments.net/reader033/viewer/2022052700/55c8c4cbbb61ebda1c8b46e5/html5/thumbnails/49.jpg)
Baseball historians consider Gibson to be among the very best
and power hitters and catchers in the history
of any league
Josh Gibson Died 35 y old
Stroke
![Page 50: ueda2013 primary prevention-d.lobna](https://reader033.fdocuments.net/reader033/viewer/2022052700/55c8c4cbbb61ebda1c8b46e5/html5/thumbnails/50.jpg)
0 1 2 3 4
1
2
3
4
5
6
Number at Risk
Rosuvastatin
Placebo
8,901 8,640 8,426 6,550 3,905 1,966 1,359 989 547 158
8,901 8,641 8,390 6,542 3,895 1,977 1,346 963 538 176
JUPITER:
Bypass Surgery or PTCA / Hospitalization for UA
Follow-up Years
Cu
mu
lati
ve In
cid
en
ce,
%
Rosuvastatin Placebo
HR 0.53 (95% CI 0.40-0.70) P<0.00001
- 47 %
Number of events 76 143
![Page 51: ueda2013 primary prevention-d.lobna](https://reader033.fdocuments.net/reader033/viewer/2022052700/55c8c4cbbb61ebda1c8b46e5/html5/thumbnails/51.jpg)
Bill Clinton Former USA President Bypass surgery and 2 stints At the age of 50’s
Mohamed Hamaki Egyptian Singer 2 coronaryt stints At the age of 30’s
![Page 52: ueda2013 primary prevention-d.lobna](https://reader033.fdocuments.net/reader033/viewer/2022052700/55c8c4cbbb61ebda1c8b46e5/html5/thumbnails/52.jpg)
JUPITER
Myocardial Infarction, Stroke, Cardiovascular Death
Placebo (N = 157)
Rosuvastatin (N = 83)
HR 0.53, 95%CI 0.40-0.69
P < 0.00001
- 47 %
0 1 2 3 4
0.0
0
0.0
1
0.0
2
0.0
3
0.0
4
0.0
5
Cu
mu
lati
ve In
cid
en
ce
Number at Risk Follow-up (years)
Rosuvastatin
Placebo
8,901 8,643 8,437 6,571 3,921 1,979 1,370 998 551 159
8,901 8,633 8,381 6,542 3,918 1,992 1,365 979 550 181
![Page 53: ueda2013 primary prevention-d.lobna](https://reader033.fdocuments.net/reader033/viewer/2022052700/55c8c4cbbb61ebda1c8b46e5/html5/thumbnails/53.jpg)
Sheikh Sayed Tantawy SHEIKH EL AZHAR Died in KSA Heart Attack - 2011
Galal Amer writer Died in a demonstration Heart Attack - 2012
![Page 54: ueda2013 primary prevention-d.lobna](https://reader033.fdocuments.net/reader033/viewer/2022052700/55c8c4cbbb61ebda1c8b46e5/html5/thumbnails/54.jpg)
JUPITER:
Death from Any Cause
Rosuvastatin
Placebo 8901 8782 4323 1613 683
8901 8787 4313 1601 682
Number at risk Years
0
1
2
3
4
5
6
7
0 1 2 3 4 6
Cu
mu
lati
ve In
cid
ence
, %
HR 0.80 (95% CI 0.67−0.97) P=0.021
Rosuvastatin Placebo
Number of events 198 247
- 20 %
![Page 55: ueda2013 primary prevention-d.lobna](https://reader033.fdocuments.net/reader033/viewer/2022052700/55c8c4cbbb61ebda1c8b46e5/html5/thumbnails/55.jpg)
VENOUS THROMBOSIS IN JUPITER
![Page 56: ueda2013 primary prevention-d.lobna](https://reader033.fdocuments.net/reader033/viewer/2022052700/55c8c4cbbb61ebda1c8b46e5/html5/thumbnails/56.jpg)
JUPITER
Total Venous Thromboembolism
0 1 2 3 4
0.0
00
0
.00
5
0.0
10
0
.01
5
0.0
20
0
.02
5
Cu
mu
lati
ve In
cid
en
ce
Number at Risk Follow-up (years)
Rosuvastatin
Placebo
8,901 8,648 8,447 6,575 3,927 1,986 1,376 1,003 548 161
8,901 8,652 8,417 6,574 3,943 2,012 1,381 993 556 182
HR 0.57, 95%CI 0.37-0.86
P= 0.007
Placebo 60 / 8901
Rosuvastatin 34 / 8901
- 43 %
Glynn et al NEJM 2009
![Page 57: ueda2013 primary prevention-d.lobna](https://reader033.fdocuments.net/reader033/viewer/2022052700/55c8c4cbbb61ebda1c8b46e5/html5/thumbnails/57.jpg)
It isn’t LDL alone, Not inflammation alone , it is both
![Page 58: ueda2013 primary prevention-d.lobna](https://reader033.fdocuments.net/reader033/viewer/2022052700/55c8c4cbbb61ebda1c8b46e5/html5/thumbnails/58.jpg)
0
1
2
3
4
5
hsC
RP
(m
g/L
)
0
20
40
60
80
100
120
140
LDL
(m
g/d
L)
Months 0 12 24 36 48
0
10
20
30
40
50
60
0
20
40
60
80
100
120
140
0 12 24 36 48
TG (
mg/
dL)
H
DL
(mg
/dL)
Months
JUPITER Effects of rosuvastatin 20 mg on LDL, HDL, TG, and hsCRP
LDL decrease 50 percent at 12 months
hsCRP decrease 37 percent at 12 months
HDL increase 4 percent at 12 months
TG decrease 17 percent at 12 months
Ridker et al NEJM 2008
![Page 59: ueda2013 primary prevention-d.lobna](https://reader033.fdocuments.net/reader033/viewer/2022052700/55c8c4cbbb61ebda1c8b46e5/html5/thumbnails/59.jpg)
JUPITER LDL reduction, hsCRP reduction, or both?
N Rate Placebo 7832 1.11 LDL Achieved > 70 mg/dL 2110 0.91 LDL Achieved < 70 mg/dL 5606 0.51 Placebo LDL Reduction < 50 % LDL Reduction > 50 % Placebo hsCRP Achieved > 2 mg/L hsCRP Achieved < 2 mg/L Placebo hsCRP Reduction < 50 % hsCRP Reduction > 50 %
P < 0.001
1.0 0.5 0.25 2.0 4.0
Rosuvastatin Better
Rosuvastatin Worse
![Page 60: ueda2013 primary prevention-d.lobna](https://reader033.fdocuments.net/reader033/viewer/2022052700/55c8c4cbbb61ebda1c8b46e5/html5/thumbnails/60.jpg)
JUPITER LDL reduction, hsCRP reduction, or both?
N Rate Placebo 7832 1.11 LDL Achieved > 70 mg/dL 2110 0.91 LDL Achieved < 70 mg/dL 5606 0.51 Placebo 7832 1.11 LDL Reduction < 50 % 4181 0.74 LDL Reduction > 50 % 3535 0.47 Placebo hsCRP Achieved > 2 mg/L hsCRP Achieved < 2 mg/L Placebo hsCRP Reduction < 50 % hsCRP Reduction > 50 %
P < 0.001
P < 0.001
1.0 0.5 0.25 2.0 4.0
Rosuvastatin Better
Rosuvastatin Worse
![Page 61: ueda2013 primary prevention-d.lobna](https://reader033.fdocuments.net/reader033/viewer/2022052700/55c8c4cbbb61ebda1c8b46e5/html5/thumbnails/61.jpg)
JUPITER LDL reduction, hsCRP reduction, or both? N Rate
Placebo 7832 1.11 LDL Achieved > 70 mg/dL 2110 0.91 LDL Achieved < 70 mg/dL 5606 0.51 Placebo 7832 1.11 LDL Reduction < 50 % 4181 0.74 LDL Reduction > 50 % 3535 0.47 Placebo 7832 1.11 hsCRP Achieved > 2 mg/L 4305 0.77 hsCRP Achieved < 2 mg/L 3411 0.42 Placebo hsCRP Reduction < 50 % hsCRP Reduction > 50 %
P < 0.001
P < 0.001
1.0 0.5 0.25 2.0 4.0
P < 0.001
Rosuvastatin Better
Rosuvastatin Worse
![Page 62: ueda2013 primary prevention-d.lobna](https://reader033.fdocuments.net/reader033/viewer/2022052700/55c8c4cbbb61ebda1c8b46e5/html5/thumbnails/62.jpg)
JUPITER LDL reduction, hsCRP reduction, or both? N Rate
Placebo 7832 1.11 LDL Achieved > 70 mg/dL 2110 0.91 LDL Achieved < 70 mg/dL 5606 0.51 Placebo 7832 1.11 LDL Reduction < 50 % 4181 0.74 LDL Reduction > 50 % 3535 0.47 Placebo 7832 1.11 hsCRP Achieved > 2 mg/L 4305 0.77 hsCRP Achieved < 2 mg/L 3411 0.42 Placebo 7832 1.11 hsCRP Reduction < 50 % 4143 0.70 hsCRP Reduction > 50 % 3573 0.51
P < 0.001
P < 0.001
1.0 0.5 0.25 2.0 4.0
P < 0.001
P < 0.001
Rosuvastatin Better
Rosuvastatin Worse
![Page 63: ueda2013 primary prevention-d.lobna](https://reader033.fdocuments.net/reader033/viewer/2022052700/55c8c4cbbb61ebda1c8b46e5/html5/thumbnails/63.jpg)
JUPITER LDL reduction, hsCRP reduction, or both?
N Rate Placebo LDL>70mg/dL,hsCRP>2 mg/L LDL<70mg/dL,hsCRP>2 mg/L LDL>70mg/dL,hsCRP<2 mg/L LDL<70mg/dL,hsCRP<2 mg/L Placebo LDL>70mg/dL,hsCRP>1 mg/L LDL<70mg/dL,hsCRP>1 mg/L LDL>70mg/dL,hsCRP<1 mg/L LDL<70mg/dL,hsCRP<1 mg/L
1.0 0.5 0.25 2.0 4.0
Rosuvastatin Better
Rosuvastatin Worse
![Page 64: ueda2013 primary prevention-d.lobna](https://reader033.fdocuments.net/reader033/viewer/2022052700/55c8c4cbbb61ebda1c8b46e5/html5/thumbnails/64.jpg)
JUPITER LDL reduction, hsCRP reduction, or both?
N Rate Placebo 7832 1.11 LDL>70mg/dL,hsCRP>2 mg/L 1384 1.11 LDL<70mg/dL,hsCRP>2 mg/L 2921 0.62 LDL>70mg/dL,hsCRP<2 mg/L 726 0.54 LDL<70mg/dL,hsCRP<2 mg/L 2685 0.38 Placebo LDL>70mg/dL,hsCRP>1 mg/L LDL<70mg/dL,hsCRP>1 mg/L LDL>70mg/dL,hsCRP<1 mg/L LDL<70mg/dL,hsCRP<1 mg/L
1.0 0.5 0.25 2.0 4.0
P < 0.001
Rosuvastatin Better
Rosuvastatin Worse
![Page 65: ueda2013 primary prevention-d.lobna](https://reader033.fdocuments.net/reader033/viewer/2022052700/55c8c4cbbb61ebda1c8b46e5/html5/thumbnails/65.jpg)
JUPITER LDL reduction, hsCRP reduction, or both?
N Rate Placebo 7832 1.11 LDL>70mg/dL,hsCRP>2 mg/L 1384 1.11 LDL<70mg/dL,hsCRP>2 mg/L 2921 0.62 LDL>70mg/dL,hsCRP<2 mg/L 726 0.54 LDL<70mg/dL,hsCRP<2 mg/L 2685 0.38 Placebo 7832 1.11 LDL>70mg/dL,hsCRP>1 mg/L 1874 0.95 LDL<70mg/dL,hsCRP>1 mg/L 4662 0.56 LDL>70mg/dL,hsCRP<1 mg/L 236 0.64 LDL<70mg/dL,hsCRP<1 mg/L 944 0.24
1.0 0.5 0.25 2.0 4.0
P < 0.001
Rosuvastatin Better
Rosuvastatin Worse
P < 0.001
![Page 66: ueda2013 primary prevention-d.lobna](https://reader033.fdocuments.net/reader033/viewer/2022052700/55c8c4cbbb61ebda1c8b46e5/html5/thumbnails/66.jpg)
Treating Average risk People : Is it cost Effective ?
![Page 67: ueda2013 primary prevention-d.lobna](https://reader033.fdocuments.net/reader033/viewer/2022052700/55c8c4cbbb61ebda1c8b46e5/html5/thumbnails/67.jpg)
Ridker et al. Circulation CV Qual Outcomes 2009;2: 616-23.
Benchmarks: Statins for hyperlipidemia 5-year NNT 40-60 Diuretics 5-year NNT 80-100 Beta-blockers 5-year NNT 120-160 Aspirin Men 5-year NNT 220-270 Aspirin Women 5-year NNT 280-330
JUPITER: Number Needed to Treat (5 year)
Endpoint All FRS≤10 FRS>10
Primary Endpoint 25 47 17
Primary Endpoint, Mortality 20 34 14
MI, Stroke, CABG/PTCA, Death 20 37 14
MI, Stroke, Death 29 60 20
![Page 68: ueda2013 primary prevention-d.lobna](https://reader033.fdocuments.net/reader033/viewer/2022052700/55c8c4cbbb61ebda1c8b46e5/html5/thumbnails/68.jpg)
0
50
100
150
200
250
300
350
400
450
Estimated 5-Year NNT Values for the Primary Prevention of Cardiovascular Disease In Middle-Aged Populations
![Page 69: ueda2013 primary prevention-d.lobna](https://reader033.fdocuments.net/reader033/viewer/2022052700/55c8c4cbbb61ebda1c8b46e5/html5/thumbnails/69.jpg)
Rosuvastatin Vs other statins
![Page 70: ueda2013 primary prevention-d.lobna](https://reader033.fdocuments.net/reader033/viewer/2022052700/55c8c4cbbb61ebda1c8b46e5/html5/thumbnails/70.jpg)
CRESTOR® versus Comparators: LDL-C Efficacy at 10mg Dose
The STELLAR Study
Change in LDL-C from baseline (%)
0 –10 –20 –30 –40 –50 –60
10 mg *
–5 –15 –25 –35 –45 –55
20 mg †
40 mg ‡
10 mg
20 mg
80 mg
10 mg
20 mg
40 mg
80 mg
10 mg
20 mg
40 mg Rosuvastatin 10 mg (–46%)
Rosuvastatin
Atorvastatin
Simvastatin
Pravastatin
40 mg
*p<0.002 vs atorvastatin 10 mg; simvastatin 10, 20, 40 mg; pravastatin 10, 20, 40 mg †p<0.002 vs atorvastatin 20, 40 mg; simvastatin 20, 40, 80 mg; pravastatin 20, 40 mg ‡p<0.002 vs atorvastatin 40 mg; simvastatin 40, 80 mg; pravastatin 40 mg Adapted from Jones PH et al. Am J Cardiol 2003;92:152–160
![Page 71: ueda2013 primary prevention-d.lobna](https://reader033.fdocuments.net/reader033/viewer/2022052700/55c8c4cbbb61ebda1c8b46e5/html5/thumbnails/71.jpg)
Statins: TC/HDL-C Ratio Efficacy Across the Dose Range
Jones PH, et al. for the Statin Therapies for Elevated Lipid Levels compared Across doses to Rosuvastatin (STELLAR) Study Group. Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: Additional results from the STELLAR trial. Clinical Therapeutics 2004;26(9):1388-1399.
*p<0.002 vs equivalent parts of the authorized doses of comparators
![Page 72: ueda2013 primary prevention-d.lobna](https://reader033.fdocuments.net/reader033/viewer/2022052700/55c8c4cbbb61ebda1c8b46e5/html5/thumbnails/72.jpg)
CRESTOR® versus atorvastatin - change in HDL-C across the dose range
The STELLAR Study
*p<0.002 vs atorvastatin 20, 40 and 80 mg †p<0.002 vs atorvastatin 40 and 80 mg Adapted from Jones PH et al. Am J Cardiol 2003;92:152–160
0
2
4
6
8
10
12
10
Atorvastatin
Rosuvastatin
20 40 80
ns
*
†
n=473
n=634
Dose (mg); log scale
Ch
ange
in H
DL-
C f
rom
b
ase
line
(%
)
![Page 73: ueda2013 primary prevention-d.lobna](https://reader033.fdocuments.net/reader033/viewer/2022052700/55c8c4cbbb61ebda1c8b46e5/html5/thumbnails/73.jpg)
Jupiter confirms safety
![Page 74: ueda2013 primary prevention-d.lobna](https://reader033.fdocuments.net/reader033/viewer/2022052700/55c8c4cbbb61ebda1c8b46e5/html5/thumbnails/74.jpg)
![Page 75: ueda2013 primary prevention-d.lobna](https://reader033.fdocuments.net/reader033/viewer/2022052700/55c8c4cbbb61ebda1c8b46e5/html5/thumbnails/75.jpg)
Data from prescribing information for atorvastatin, simvastatin, and rosuvastatin. Clinical Advisory on Statins.
This does not represent data from a comparative study.
LDL vs Incidence of Elevated Transaminases
80 mg 40 mg 20 mg
simvastatin 80 mg 40 mg 20 mg
-48%
-34% -29%
10 mg 20 mg 40 mg 80 mg
atorvastatin 10 mg 20 mg 40 mg 80 mg
-55% -51%
-46%
-38%
0.0
0.5
1.0
1.5
2.0
2.5
Elev
ated
tr
ansa
min
ase
s (%
of
pat
ien
ts)
% d
ecre
ase
in L
DL-
C
-60
-50
-40
-30
-20
-10
0
-70
40 mg 20 mg 10 mg
rosuvastatin 40 mg 20 mg 10 mg
-52%
-55%
-63%
Risk Benefits
decrease in LDL-C
![Page 76: ueda2013 primary prevention-d.lobna](https://reader033.fdocuments.net/reader033/viewer/2022052700/55c8c4cbbb61ebda1c8b46e5/html5/thumbnails/76.jpg)
0.0
0.5
1.0
1.5
2.0
2.5
3.0
20 30 40 50 60 70
LDL-C reduction (%)
Fluvastatin (20, 40, 80 mg)
Rosuvastatin (5, 10, 20, 40 mg)
Lovastatin (20, 40, 80 mg)
Atorvastatin (10, 20, 40, 80 mg) Simvastatin (40, 80 mg)
ALT >3 × ULN: Frequency by LDL-C reduction1,2
Occ
urr
en
ce o
f A
LT >
3×
ULN
(%
)
Persistent elevation is elevation to >3 x ULN on 2 successive occasions 1. Brewer H Am J Cardiol 2003;92(Suppl):23K–29K 2. Davidson M Exp Opin Drug Saf 2004;3 (6):547-557
CRESTOR® safety;
Liver effects - Benefit:Risk
![Page 77: ueda2013 primary prevention-d.lobna](https://reader033.fdocuments.net/reader033/viewer/2022052700/55c8c4cbbb61ebda1c8b46e5/html5/thumbnails/77.jpg)
CRESTOR® safety;
Muscle effects - Benefit:Risk
CK >10 x ULN: Frequency by LDL-C Reduction1,2
0.0
0.5
1.0
1.5
2.0
2.5
3.0
20 30 40 50 60 70
LDL-C reduction (%)
Occ
urr
en
ce o
f C
K >
10
× U
LN (
%)
Cerivastatin (0.2, 0.3, 0.4, 0.8 mg)
Rosuvastatin (5, 10, 20, 40 mg)
Pravastatin (20, 40 mg)
Atorvastatin (10, 20, 40, 80 mg) Simvastatin (40, 80 mg)
1.Brewer H Am J Cardiol 2003;92(Suppl):23K–29K 2.Davidson M Exp Opin Drug Saf 2004;3 (6):547-557
![Page 78: ueda2013 primary prevention-d.lobna](https://reader033.fdocuments.net/reader033/viewer/2022052700/55c8c4cbbb61ebda1c8b46e5/html5/thumbnails/78.jpg)
Jupiter turning guidelines upside down
![Page 79: ueda2013 primary prevention-d.lobna](https://reader033.fdocuments.net/reader033/viewer/2022052700/55c8c4cbbb61ebda1c8b46e5/html5/thumbnails/79.jpg)
JUPITER
Public Health Implications
Application of the simple screening and treatment strategy tested in the JUPITER trial over a five-year period could conservatively prevent more than 250,000 heart attacks, strokes, revascularization procedures, and cardiovascular deaths in the United States alone.
Ridker et al NEJM 2008
![Page 80: ueda2013 primary prevention-d.lobna](https://reader033.fdocuments.net/reader033/viewer/2022052700/55c8c4cbbb61ebda1c8b46e5/html5/thumbnails/80.jpg)
Primary endpoint* data from major placebo-controlled statin outcomes studies correlating risk reduction with LDL-C
reduction
Fabbri G, Maggioni AP. Adv Ther. 2009; 26: 469–487 Copyright 2009. With kind permission from Springer Science and Business Media.
Rela
tive r
isk r
ed
ucti
on
(%
)
% Reduction in LDL-C
0 10 20 30 40 50 60
0
10
20
30
40
50
60
AF/TEX ASCOT JUPITER
CARDS
LIPS CARE
SPARCL ALERT
ASPEN PROSPER
WOSCOPS
LIPID
HPS
Regression line through the origin
95% confidence limits
4S
*is proportional to the number of paPrimary endpoint used for all studies, with the exception of 4S (major coronary events), HPS (major vascular event), LIPID (CHD death or nonfatal MI), SPARCL (major CV event. ) The area of the plotted symbol tients in the study
![Page 81: ueda2013 primary prevention-d.lobna](https://reader033.fdocuments.net/reader033/viewer/2022052700/55c8c4cbbb61ebda1c8b46e5/html5/thumbnails/81.jpg)
None of these patients are currently recommended to receive statin therapy because they have Framingham 10-year risk <20% AND LDL-C levels below the treatment target (ie < 130 mg/dL). All have hsCRP > 2 mg/L.
JUPITER: Public Health Implications: Primary Endpoint at “Intermediate Risk”
FRS (%) Rosuvastatin Placebo HR 95% CI
5–10%
(N=6091) 32 (0.50) 59 (0.92) 0.55 (0.36-0.84)
10–20%
(N=7340) 74 (0.95) 145 (1.84) 0.51 (0.39-0.68)
![Page 82: ueda2013 primary prevention-d.lobna](https://reader033.fdocuments.net/reader033/viewer/2022052700/55c8c4cbbb61ebda1c8b46e5/html5/thumbnails/82.jpg)
2009 Canadian Cardiovascular Society (CCS) Guidelines for the Diagnosis and Treatment of Dyslipidemia and
Prevention of Cardiovascular Disease in the Adult
Primary Goal: LDLC
High CAD, CVA, PVD
Most pts with Diabetes
FRS >20%
RRS >20%
<2 mmol/L or 50%
reduction
Class I
Level A
Moderate FRS 10-19%
RRS 10-19%
LDL >3.5 mmol/L
TC/HDLC >5.0
hsCRP >2 in
men >50 yr
women >60 yr
<2 mmol/L or 50%
reduction
Class IIA
Level A
Low FRS <10% <5 mmol/L Class IIA
Level A
Secondary Targets TC/HDLC <4, non HDLC <3.5 mol/L
hsCRP <2 mg/L, TG <1.7 mol/L, ApoB/A <0.8
![Page 83: ueda2013 primary prevention-d.lobna](https://reader033.fdocuments.net/reader033/viewer/2022052700/55c8c4cbbb61ebda1c8b46e5/html5/thumbnails/83.jpg)
![Page 84: ueda2013 primary prevention-d.lobna](https://reader033.fdocuments.net/reader033/viewer/2022052700/55c8c4cbbb61ebda1c8b46e5/html5/thumbnails/84.jpg)
Male Above 50 Smoker Regardless to TC Is High Risk
![Page 85: ueda2013 primary prevention-d.lobna](https://reader033.fdocuments.net/reader033/viewer/2022052700/55c8c4cbbb61ebda1c8b46e5/html5/thumbnails/85.jpg)
Take Home Messages
• We should start assessing patients at increased risk
• Treat to target LDL-C or 50% reduction in LDL-C
• Based on Jupiter , FDA approved CRESTOR 20 mg for patients who are at increased risk of heart disease but have not been diagnosed with it.
• Jupiter showed a significant reduction in the first occurrence of any major cardiovascular event by 44%
• Jupiter showed a significant reduction in non fatal MI by 65%
![Page 86: ueda2013 primary prevention-d.lobna](https://reader033.fdocuments.net/reader033/viewer/2022052700/55c8c4cbbb61ebda1c8b46e5/html5/thumbnails/86.jpg)
THANKS